Key facts
- It has raised $18.0M; the latest was Later Stage VC in Oct 2025.
- Notable investors include University of Toronto, University of Toronto Entrepreneurship, The Production Board, BEVC (Berkeley), QB3 — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Dextera Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Dextera Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dextera Biosciences
Developer of a biotechnology platform intended to develop new classes of protein-based therapeutics. The company's platform offers new drug entities that are non-immunogenic and inherently resistant to proteolysis, vastly improving pharmacokinetics that precisely target the site of disease while remaining invisible to the rest of the body, enabling patients to receive therapeutics to recover from chronic diseases.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2008
- Employees
- 14
- Website
- dexterabio.com/
- Ownership
- Privately Held (backing)
Dextera Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dextera Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dextera Biosciences in its N-PORT filings yet. We sweep new filings monthly.